| Dr Todd Andrew Meyer, DO | |
|
1501 S Madison St, Appleton, WI 54915-1846 | |
| (920) 730-4443 | |
| Not Available |
| Full Name | Dr Todd Andrew Meyer |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 27 Years |
| Location | 1501 S Madison St, Appleton, Wisconsin |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1306863014 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207YX0905X | Otolaryngology - Otolaryngology/facial Plastic Surgery | 5101013421 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Ascension Ne Wisconsin - St Elizabeth Campus | Appleton, WI | Hospital |
| Thedacare Regional Medical Center - Appleton Inc | Appleton, WI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ear Nose And Throat Specialists Of Wisconsin Sc | 9830086925 | 22 |
News Archive
Doubts about their ability to become pregnant affect as many as 25 percent of American women, and solving that problem is the basic business plan for BluDiagnostics. Although the startup company was born in the University of Wisconsin-Madison Biochemistry Department, co-founder Katie Brenner says the idea came directly from her own difficulty with conception.
Net sales decreased 8.8% to $123.9 million in the second quarter of 2009 compared with $135.8 million in the second quarter of 2008. Income from operations was $16.6 million in the second quarter of 2009, compared to $16.0 million in the second quarter of 2008. Net loss was $1.2 million in the second quarter of 2009, compared with a net loss of $1.3 million in the second quarter of 2008.
One of the human body's protective mechanisms initiated by the TRAIL protein is massively altered in prostate cancer cells - yet the same protein seems to improve the survival prospects of patients. These outstanding results of a cooperative venture between the Clinical Program on Urological Tumours at the Medical University of Vienna and Harvard Medical School, USA, have just been published. They show that the TRAIL protein opens up the prospect to a more accurate prediction of the disease's course, as well as the opportunity to identify a new intervention point for innovative therapies in advanced prostate cancer.
Drug approvals are taking just as long as they ever did despite increased expenditure on new information technology at the Food and drug Administration. So says a statistical analysis of approval intervals from 1997 to 2006, published in the International Journal of Electronic Healthcare.
› Verified 6 days ago
| Entity Name | Ear Nose And Throat Specialists Of Wisconsin Sc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508819178 PECOS PAC ID: 9830086925 Enrollment ID: O20040303000262 |
News Archive
Doubts about their ability to become pregnant affect as many as 25 percent of American women, and solving that problem is the basic business plan for BluDiagnostics. Although the startup company was born in the University of Wisconsin-Madison Biochemistry Department, co-founder Katie Brenner says the idea came directly from her own difficulty with conception.
Net sales decreased 8.8% to $123.9 million in the second quarter of 2009 compared with $135.8 million in the second quarter of 2008. Income from operations was $16.6 million in the second quarter of 2009, compared to $16.0 million in the second quarter of 2008. Net loss was $1.2 million in the second quarter of 2009, compared with a net loss of $1.3 million in the second quarter of 2008.
One of the human body's protective mechanisms initiated by the TRAIL protein is massively altered in prostate cancer cells - yet the same protein seems to improve the survival prospects of patients. These outstanding results of a cooperative venture between the Clinical Program on Urological Tumours at the Medical University of Vienna and Harvard Medical School, USA, have just been published. They show that the TRAIL protein opens up the prospect to a more accurate prediction of the disease's course, as well as the opportunity to identify a new intervention point for innovative therapies in advanced prostate cancer.
Drug approvals are taking just as long as they ever did despite increased expenditure on new information technology at the Food and drug Administration. So says a statistical analysis of approval intervals from 1997 to 2006, published in the International Journal of Electronic Healthcare.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Todd Andrew Meyer, DO 119 E Bell St, Neenah, WI 54956-4993 Ph: (757) 636-2923 | Dr Todd Andrew Meyer, DO 1501 S Madison St, Appleton, WI 54915-1846 Ph: (920) 730-4443 |
News Archive
Doubts about their ability to become pregnant affect as many as 25 percent of American women, and solving that problem is the basic business plan for BluDiagnostics. Although the startup company was born in the University of Wisconsin-Madison Biochemistry Department, co-founder Katie Brenner says the idea came directly from her own difficulty with conception.
Net sales decreased 8.8% to $123.9 million in the second quarter of 2009 compared with $135.8 million in the second quarter of 2008. Income from operations was $16.6 million in the second quarter of 2009, compared to $16.0 million in the second quarter of 2008. Net loss was $1.2 million in the second quarter of 2009, compared with a net loss of $1.3 million in the second quarter of 2008.
One of the human body's protective mechanisms initiated by the TRAIL protein is massively altered in prostate cancer cells - yet the same protein seems to improve the survival prospects of patients. These outstanding results of a cooperative venture between the Clinical Program on Urological Tumours at the Medical University of Vienna and Harvard Medical School, USA, have just been published. They show that the TRAIL protein opens up the prospect to a more accurate prediction of the disease's course, as well as the opportunity to identify a new intervention point for innovative therapies in advanced prostate cancer.
Drug approvals are taking just as long as they ever did despite increased expenditure on new information technology at the Food and drug Administration. So says a statistical analysis of approval intervals from 1997 to 2006, published in the International Journal of Electronic Healthcare.
› Verified 6 days ago
Dr. Steven James Vandenberg, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1520 N Meade St, Appleton, WI 54911 Phone: 920-734-7181 Fax: 920-734-0621 | |
Dr. Mitchell Francis Kwaterski, M.D. Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 1520 N Meade St, Appleton, WI 54911 Phone: 920-734-7181 Fax: 920-734-0621 | |
Dr. Matthew Edward Bettag, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1520 N Meade St, Appleton, WI 54911 Phone: 920-734-7181 Fax: 920-734-0621 | |
Dr. Michael James Mcavoy, D. O. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1520 N Meade St, Appleton, WI 54911 Phone: 920-734-7181 Fax: 920-734-0621 | |
Gregory J Swanson, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1501 S Madison St, Appleton, WI 54915 Phone: 920-730-4443 | |
Dr. Ryan Timothy Funk, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 247 S Nicolet Rd, Appleton, WI 54914 Phone: 888-938-3838 Fax: 888-919-1083 |